U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H35Cl2N3O2
Molecular Weight 552.535
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SAREDUTANT

SMILES

CN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C2=CC=CC=C2)C3=CC=C(Cl)C(Cl)=C3)C(=O)C4=CC=CC=C4

InChI

InChIKey=PGKXDIMONUAMFR-AREMUKBSSA-N
InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C31H35Cl2N3O2
Molecular Weight 552.535
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Sanofi aventis developed saredutant (also known as SR 48968C) as a tachykinin neurokinin-2 (NK2) receptor antagonist for the treatment of depressive disorders and generalized anxiety disorder. This drug participated in phase III clinical trials in patients with a generalized anxiety disorder and as Combination Treatment for major depressive disorder, however, the drug failed to meet efficacy endpoints. It is known that NK-2 receptor mediates airway obstruction that is why saredutant was studied as a potential treatment of asthma. However, all studies of the drug were discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery.
2010-11-26
ACS chemical neuroscience molecule spotlight on Saredutant.
2010-10-20
Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights.
2010-09-20
Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression.
2010-08
Contractile responses induced by physalaemin, an analogue of substance P, in the rat esophagus.
2010-02-25
Involvement of sensory nerves and TRPV1 receptors in the rat airway inflammatory response to two environment pollutants: diesel exhaust particles (DEP) and 1,2-naphthoquinone (1,2-NQ).
2010-02
Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
2009-05-01
Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
2009-05
Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions.
2008-09
Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants.
2008-08-15
Capsaicin-evoked bradycardia in anesthetized guinea pigs is mediated by endogenous tachykinins.
2008-04-10
Role of tachykinin NK(1) and NK(2) receptors in colonic sensitivity and stress-induced defecation in gerbils.
2008-03-17
Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models.
2008-03
Contractile effect of tachykinins on Suncus murinus (house musk shrew) isolated ileum.
2007-11-06
Role of capsaicin-sensitive afferents and sensory neuropeptides in endotoxin-induced airway inflammation and consequent bronchial hyperreactivity in the mouse.
2007-06-07
Tachykinin receptors antagonists: from research to clinic.
2006-08
Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils.
2006-04
Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor.
2005-06-01
Inducible nitric oxide synthase evoked nitric oxide counteracts capsaicin-induced airway smooth muscle contraction, but exacerbates plasma extravasation.
2005-04-18
Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat.
2005-01-10
Targeting tachykinins for the treatment of obstructive airways disease.
2004
Actions of endothelin and corticotropin releasing factor in the guinea-pig ileum: no evidence for an interaction with capsaicin-sensitive neurons.
2003-08
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
2002-08-23
Effect of a tachykinin NK(2) receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs.
2001-03-09
Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats.
2000
Effect of tachykinin receptor antagonists in experimental neuropathic pain.
1998-11-20
Acetylcholine and tachykinin receptor antagonists attenuate wood smoke-induced bronchoconstriction in guinea pigs.
1998-11-06
Further evidence for the involvement of tachykinin receptor subtypes in formalin and capsaicin models of pain in mice.
1997-08
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
1997-06
Role of tachykinins in castor oil diarrhoea in rats.
1997-06
The non-peptide tachykinin NK1- and NK2-receptor antagonists SR 140333 and SR 48968 prevent castor-oil induced diarrhea in rats.
1996
The inhibitory modulation of guinea-pig intestinal peristalsis caused by capsaicin involves calcitonin gene-related peptide and nitric oxide.
1995-12
Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats.
1995-10
Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?
1995-06
'Sensory-efferent' neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea in vitro.
1994-12
Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction.
1994-09
Capsaicin-induced bladder hyperactivity in normal conscious rats.
1994-08
Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats.
1994-07-01
Characterization of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladder.
1994-04
The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors.
1994-02-15
Expression of rat NK-2 (neurokinin A) receptor in E. coli.
1994
Characterization of the binding sites of [3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor.
1993-03-31
Influence of (+/-)-CP-96,345 and SR 48968 on electrical field stimulation of the isolated guinea-pig main bronchus.
1992-12-02
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.
1992

Sample Use Guides

Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:55:21 GMT 2025
Edited
by admin
on Wed Apr 02 07:55:21 GMT 2025
Record UNII
720U2QK8I5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAREDUTANT
INN   WHO-DD  
INN  
Official Name English
SR-48968
Preferred Name English
BENZAMIDE, N-((2S)-4-(4-(ACETYLAMINO)-4-PHENYL-1-PIPERIDINYL)-2-(3,4-DICHLOROPHENYL)BUTYL)-N-METHYL-
Systematic Name English
saredutant [INN]
Common Name English
Saredutant [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
Code System Code Type Description
EVMPD
SUB10449MIG
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
INN
7487
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
PUBCHEM
104974
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
CAS
142001-63-6
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
WIKIPEDIA
Saredutant
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID00161923
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
SMS_ID
100000084095
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
IUPHAR
2111
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
DRUG BANK
DB06660
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
NCI_THESAURUS
C152301
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
FDA UNII
720U2QK8I5
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
ChEMBL
CHEMBL308148
Created by admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Tachykinin NK2 receptor antagonist that was developed by Sanofi-Aventis for anti-depressant potential
IC50
Related Record Type Details
ACTIVE MOIETY